![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia
Publisher: Spandidos Publications
ISSN: 1021-335X
Source: Oncology Reports, Vol.27, Iss.2, 2012-01, pp. : 461-466
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract